Intercept Pharmaceuticals Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: April 15th, 2022
Here are a few of the most interesting Intercept Pharmaceuticals statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Intercept Pharmaceuticals Facts
- Intercept Pharmaceuticals Website: Official Website
- Year Intercept Pharmaceuticals was Founded: 2002
- Intercept Pharmaceuticals Headquarters: New York City
- Current Intercept Pharmaceuticals Chief Executive: Mark Pruzanski
What is Intercept Pharmaceuticals?
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. (source)
Intercept Pharmaceuticals Employee Count
Number of Intercept Pharmaceuticals employees:
Last updated 1/1/20
Intercept Pharmaceuticals Revenue Totals
Intercept Pharmaceuticals annual revenue:
- 2021: $363 million
- 2020: $312 million
- 2019: $252 million
- 2018: $179 million
- 2017: $130 million
- 2016: $24 million
- 2015: $2 million
Intercept Pharmaceuticals annual net income:
- 2021: $91 million net loss
- 2020: $274 million net loss
- 2019: $344 million net loss
- 2018: $309 million net loss
- 2017: $360 million net loss
- 2016: $412 million net loss
- 2015: $226 million net loss
Related posts:
Please note that some of these numbers are easier to find than others. A few of these Intercept Pharmaceuticals statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags: